Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors

Cancer Immunology, Immunotherapy · Published 2021-12-01 · Available online 4 Jul 2021 · Journal article · DOI 10.1007/s00262-021-02975-8 · PMID: 34218295 · PMC · Cited by 11 (Crossref)

Authors (11)

Hamid Khodayari, Saeed Khodayari, Elmira Ebrahimi, Farimah Hadjilooei, Miko Vesovic, Habibollah Mahmoodzadeh, Tomo Saric, Wilfried Stücker, Stefaan Van Gool, Jürgen Hescheler, Karim Nayernia

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Volume

70

Issue

12

Pages

3369-3395

Year

2021

Citation

Khodayari, H., Khodayari, S., Ebrahimi, E., et al. (2021). Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-021-02975-8

Related articles

• CAR design equips diverse immune cells with unique antigen-specific activation identities · Molecular Therapy: Oncology · 2026 · Cites or is cited by this article
• Advancing CAR-NK cell therapy in solid tumors: Current landscape and future directions · Cell Reports Medicine · 2026 · Cites or is cited by this article
• HBO1 suppresses anti-tumor immunity of CD8⁺ T Cells in thyroid cancer by recruiting BRD4 to regulate VTCN1 expression · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Conserved minimal CD8 cytotoxic immune-state unit in an IL18R1-associated immune program in hepatocellular carcinoma · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Impact of neck nodal yield on immune checkpoint inhibitor outcome after recurrence in head and neck squamous cell carcinoma · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Preclinical efficacy of iPSC-derived MUC1-targeted CAR-NK cells against esophageal squamous cell carcinoma · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Survival outcomes of conversion curative therapy following atezolizumab–bevacizumab in advanced hepatocellular carcinoma · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Integrative single-cell and multi-omics analysis of ZBTB21-mediated serine metabolism in colorectal cancer: from metabolic reprogramming to immune microenvironment modulation · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Squeezing Treatment-Induced Metabolic Alterations in Melanoma Cells Are Accompanied by Impaired Cluster of Differentiation 8-Positive T Cell and Natural Killer Cell Antitumor Effector Functions · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Efficacy and safety of anti-PD-1 combined with IFN-α1b with or without anlotinib as the first-line therapy in patients with unresectable advanced melanoma: a real-world cohort study · Cancer Immunology, Immunotherapy · 2026 · Same journal

Metrics

Citations (Crossref)

11